Slide 1: Cingulate Therapeutics
Cingulate Therapeutics Developing next-generation drug candidates where standard-of- care treatments result in suboptimal outcomes 1Q 2022 A C CING-US-104-0223
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Cingulate Mission
Cingulate Mission Cingulate will develop, shape market acceptance, and prepare to commercialize next- generation drug candidates in markets where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value P
Slide 4: Targeting Treatment of ADHD - $18Bn US Market Opportunity
Targeting Treatment of ADHD - $18Bn US Market Opportunity Frequently diagnosed, chronic pattern interfering with functioning / development ~17 Million US ADHD Societal Impact of ADHD Patients Estimated annual incremental costs of $143 to $266 billion in the United States Adult ADHD Children & Adoles
Slide 5: $18 Billion US ADHD Market Dominated by Stimulants
$18 Billion US ADHD Market Dominated by Stimulants Stimulants 91% of US Market $15.3B v i i i ients’ 70 Millian Preser prions per Year Despite multitude of options, patients needs are still not being met even by Methylphenidates the most widely prescribed extended- Amphetamines ‘ : release ADHD medi
Slide 6: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products Major Unmet Medical Needs Persist ADHD : , naanias ATTRIBUTES UNMET NEE! Fast Onset of Duration Action Entire Active- Minimize Onset (less onset) < 30 min Day Efficacy* Crash/Rebound Avoid Booster? Vyvanse® 2007 2hours 12 hours x x Datei Net x
Slide 7: ADHD Market Leaders Do Not Provide “Built-In Booster”
ADHD Market Leaders Do Not Provide “Built-In Booster” Market Leaders Stop Delivery of Medication 4-5 Hours After Administration ADHD ; , BRANDS ATTRIBUTES RELEASE PROFILES Duration nn DOSE 1 / STYLE / TIME DOSE 2/ STYLE / TIME DOSE 3 / STYLE /TIME 100% PRODRUG SUSTAINED RELEASE OVER 2 - 3 HOURS Vyva
Slide 8: Recent Launches Lack Meaningful Clinical Innovation
Recent Launches Lack Meaningful Clinical Innovation Niche Delivery Platforms — Designed to Fail in ADHD ADHD BRANDS ATTRIBUTES' UNMET NEEDS Fast Acting Entire Active- Avi Avoid Product Onset Duration 30 min) Day Efficacy* Crash/Rebou Booster Quillivant / Chew® XR 60 mins 8 hours Mydayis® 2or4 hrs 16
Slide 9: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers YESMASTERY” Y$SACCOMPLISH® CTx-1301 CTx-1302 CING-US-104-0223
Slide 10: Cingulate’s Precision Timed Release™ Platform Technology
Cingulate’s Precision Timed Release™ Platform Technology Disruptive Technology Changing the Paradigm of Oral Drug Delivery Our current pipeline candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form, smaller than many single dose ADHD product
Slide 11: Unmet Needs Persist in ADHD
Unmet Needs Persist in ADHD NO ADHD product available today PTR technology affords our product candidates the combines all unmet needs following potential advantages over currently available ADHD treatments Provide ‘entire active-day’ efficacy Reduce abuse / diversion by eliminating booster v Fast o
Slide 12: CTx-1301 (dMPH) and CTx-1302 (dAMP)
CTx-1301 (dMPH) and CTx-1302 (dAMP) Ideal Design Provides Exclusive Ability to Overcome Unmet Needs TARGET ATTRIBUTI RELEASE PROFILES Duration DOSE 1 / STYLE / TIME DOSE 2 / STYLE / TIME DOSE 3 / STYLE /TIME P 45% SUSTAINED RELEASE OVER 90 20% IMMEDIATE CTx-1301 30 mins 14-16 hours 35% IMMEDIATE REL
Slide 13: CTx-1301 Clinical Phase Study Results
CTx-1301 Clinical Phase 2 Study Results Plasma dexmethylphenidate (AMPH) Concentration vs Time Extends duration for ‘entire active-day’ without Low Dose the booster dose! 3000 - Results demonstrate fast onset with the desired Fast Onset controlled descent 2500 Minimize ‘crash/rebound' effect, common
Slide 14: At the Individual Level, Tri-modal Delivery is Clear
At the Individual Level, Tri-modal Delivery is Clear Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate the Booster Dose Subject ID: 01-504 Subject ID: 01-510 —— CTx-1301 6.25-mg 2500 —®— CTx-1301 6.25-mg —@— Focalin XR 5-mg —e— Focalin XR 5-mg —* T1301 50-mg —®— Focalin XR 40-mg —— CTx
Slide 15: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE’s related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse
Slide 16: Planned Phase Trials
<MASTERY. Planned Phase 3 Trials 2019 - 2021 2022 2023 2024 Phase 1 & 2 Formulation Comparative BA Study NDA Preparation & Filing Pediatric / Pediatric Adolescent Efficacy & Fixed-Dose, Safety Placebo- Onset / Controlled Trial Duration n=300 n~50 Exploratory Endpoints Target dates; actual timelineim
Slide 17: Cingulate Commercialization Strategy
Cingulate Commercialization Strategy Changing dynamics in ADHD commercial landscape + Vyvanse loss of exclusivity ~August 2023 * Concerta, Adderall XR, Focalin XR are all off- patent with no promotion * New entrants lack major promotional efforts, field forces and revenue + PBM's driven by rebate gu
Slide 18: Exclusivity: IP, Agreements, and Trade Secrets
Exclusivity: IP, Agreements, and Trade Secrets Intellectual property rights expected to provide exclusivity through 2035 at a minimum O OralogikK™ Erosion Barrier Layer + Five (5) patents granted (US & Global) expiry dates ranging from 2031 to 2035, * One (1) OralogiK™ patent pending (US, Europe) .
Slide 19: Vast Pipeline of Next-Generation Medications Beyond ADHD
Vast Pipeline of Next-Generation Medications Beyond ADHD v Leverage our PTR platform in other therapeutics areas Y Market Criteria: © $1Bn+ in peak sales Oo Next-generation mediations with significant improvement over existing therapies Identified PTR™ Platform Pipeline Opportunities Near-Term Focus
Slide 20: Cingulate Mission
< Cingulate Mission Cingulate will develop, shape market acceptance, and prepare to commercialize next- generation drug candidates in markets where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value